Small Pharma Expands Potential of Commercial Portfolio with DMT-based Psychedelic Assets
After finding its DMT formulation to be well-tolerated, Small Pharma (DMT) is launching two new trials this year.
One will assess how DMT interacts with SSRIs in patients with depression and the other will compare the drug’s effects when administered through muscles versus veins.
The company has also developed a form of DMT that lasts longer than the typical 30 minute trip, but is still much shorter than a psilocybin or LSD trip.
Biomind Labs (BMND) is taking the opposite approach. The company reduced a DMT trip to just 10-15 minutes by making a formulation that’s inhalable.
Biomind’s formulation will be assessed in a Phase II trial for treatment-resistant depression, which just received approval by the Brazilian Institutional Review Board.
We’re eager to see if the length of the trip makes a difference!
